Business
Passing of the General Meeting of Pharma Equity Group A/S
Passing of the General Meeting of Pharma Equity Group
About this update from Pharma Equity Group A/s Class A
[{"type":"text","content":" Passing of the General Meeting of Pharma Equity Group A/S 5th of May 2025Company Announcement no. 6 Pharma Equity Group A/S held its Annual General Meeting on 16th of April 2025 with the following results: The chairman of the meeting reviewed the agenda for today's general meeting, which was:The Board of Directors’ report on the Company’s activities during the past yearPresentation of the audited annual report for approvalDischarge of the Board of Directors and Executive ManagementAdoption of the appropriation of profit or loss as proposed by the BoardPresentation of the 2024 Remuneration Report for advisory voteApproval of remuneration to the Board of Directors for the current financial yearElection of the Board of DirectorsElection of auditorProposals from the Board of Directors or shareholders A) Proposal to increase and extend the authorization to issue new shares without pre-emptive rights (section 4.1.B) B) Proposal to extend the authorization to issue warrants by one year (section 4.2) C) Proposal for approval of updated remuneration policyAuthorization to the chairman of the meetingAny other business The chairman of the meeting reviewed the adoption requirements for the various proposals on the agenda and then passed the word to the Company’s Chairman of the Board and former CEO, who presented the Board’s report.Item 1 – The Board of Directors’ report on the Company’s activities during the past yearThe Company’s former CEO, Thomas Kaas Selsø, presented the report on the Company’s activities over the past year.The chairman of the meeting asked if there were any comments or contributions regarding the report.A shareholder asked how the Market Maker agreement with Danske Bank worked, which Thomas Kaas Selsø answered. There was also a question about whether the Company had considered delisting from Nasdaq Copenhagen, to which the Board had no comment.The Company received a critical comment that the declining share price should be seen as an expression of a lack of confidence in management. Christian Vinding Thomsen and Thomas Kaas Selsø responded, stating that the decline was primarily due to a few large shareholders selling their shares.A shareholder also commented positively that the Company had secured financing in 2024 and achieved positive research results.Finally, a s...